Drug Development Pharma - November 19, 2013
Naloxegol reaches milestone
AstraZeneca has announced that the United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for naloxegol. The investigational peripherally-acting mu-opioid receptor antagonist (PAMORA) has been studied in opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, the most common side effect caused by chronic administration of prescription opioid pain […]
Drug Development Pharma - November 8, 2013
EMA seeks information on AstraZeneca’s Brilinta
The European Medicines Agency has contacted AstraZeneca asking the company to provide more information about a U.S. probe into a clinical trial of the company’s new blood thinner Brilinta (ticagrelor), reports Reuters. On November 7 EMA said that it contacted AstraZeneca earlier after the U.S. Department of Justice probe was disclosed by the company on October […]
Clinical Trials - October 25, 2013
Phase III clinical trial in NSCLC patients
AstraZeneca has announced the first patient randomized in a phase III clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) whose tumors are KRAS mutation-positive. In 2003, Array BioPharma invented and licensed the worldwide rights to develop and commercialize […]
Collaboration - October 22, 2013
AstraZeneca and Evotec launche research collaboration
AstraZeneca and Evotec have launched a research collaboration focused on developing new drugs for kidney disease, the second partnership involving entities of the pharma giant and the German drug discovery alliance and development partnership company. The value of the collaboration was not disclosed. Evotec will license a series of molecules identified by its own drug-discovery […]
Collaboration - October 16, 2013
Taris Biomedical and AstraZeneca in bladder cancer pact
TARIS Biomedical enters research collaboration with AstraZeneca for improved bladder cancer treatments. TARIS Biomedical, a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, announced today that it has entered into a research collaboration with AstraZeneca to evaluate novel treatments for bladder cancer. Under the terms of the […]
Pharma Business - September 25, 2013
AstraZeneca licenses 3 X-Chem drug discovery programs
AstraZeneca has agreed to license three drug discovery programs of X-Chem aimed at finding protein-protein interaction targets in oncology and respiratory/inflammation, as well as an antibacterial target, after achieving several milestones under a 16-month-old collaboration that was unannounced until now. The value of the programs was not disclosed, though X-Chem, which announced the licensing deal, […]
